# An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

> **NCT03810872** · PHASE2 · UNKNOWN · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 87 (estimated)

## Conditions studied

- Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03810872
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-21
- **Primary completion:** 2020-12
- **Final completion:** 2022-12
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2019-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03810872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03810872, "An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03810872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*